Arrow Financial Corp lowered its holdings in shares of Celgene Co. (NASDAQ:CELG) by 24.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,864 shares of the biopharmaceutical company’s stock after selling 4,715 shares during the quarter. Arrow Financial Corp’s holdings in Celgene were worth $953,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. Janney Capital Management LLC raised its holdings in shares of Celgene by 2.9% during the fourth quarter. Janney Capital Management LLC now owns 4,219 shares of the biopharmaceutical company’s stock valued at $270,000 after acquiring an additional 120 shares during the last quarter. Winthrop Advisory Group LLC raised its holdings in shares of Celgene by 4.1% during the fourth quarter. Winthrop Advisory Group LLC now owns 3,171 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 125 shares during the last quarter. Private Trust Co. NA raised its holdings in shares of Celgene by 2.2% during the fourth quarter. Private Trust Co. NA now owns 6,245 shares of the biopharmaceutical company’s stock valued at $400,000 after acquiring an additional 132 shares during the last quarter. Malaga Cove Capital LLC raised its holdings in shares of Celgene by 1.6% during the fourth quarter. Malaga Cove Capital LLC now owns 8,887 shares of the biopharmaceutical company’s stock valued at $566,000 after acquiring an additional 143 shares during the last quarter. Finally, Glenview State Bank Trust DEPT. raised its holdings in shares of Celgene by 1.2% during the fourth quarter. Glenview State Bank Trust DEPT. now owns 20,400 shares of the biopharmaceutical company’s stock valued at $1,308,000 after acquiring an additional 250 shares during the last quarter. Institutional investors own 75.15% of the company’s stock.
NASDAQ:CELG opened at $89.87 on Tuesday. Celgene Co. has a one year low of $58.59 and a one year high of $97.43. The company has a quick ratio of 1.99, a current ratio of 2.13 and a debt-to-equity ratio of 4.06. The company has a market capitalization of $61.66 billion, a P/E ratio of 11.81, a P/E/G ratio of 0.41 and a beta of 1.72.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.32 by $0.07. Celgene had a return on equity of 125.35% and a net margin of 26.48%. The firm had revenue of $4.04 billion during the quarter, compared to analysts’ expectations of $3.98 billion. During the same quarter last year, the firm earned $2.00 earnings per share. As a group, equities research analysts anticipate that Celgene Co. will post 10.01 earnings per share for the current year.
CELG has been the subject of a number of research analyst reports. BidaskClub cut Celgene from a “hold” rating to a “sell” rating in a report on Wednesday, October 24th. Leerink Swann cut Celgene from an “outperform” rating to a “market perform” rating in a report on Thursday, January 3rd. Mizuho set a $117.00 target price on Celgene and gave the company a “buy” rating in a report on Tuesday, October 30th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Celgene in a report on Thursday, October 25th. Finally, Robert W. Baird raised Celgene from a “neutral” rating to an “outperform” rating and set a $92.00 target price for the company in a report on Friday, January 4th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $109.29.
In related news, Director James J. Loughlin sold 23,466 shares of the stock in a transaction that occurred on Thursday, February 7th. The stock was sold at an average price of $87.29, for a total value of $2,048,347.14. Following the completion of the sale, the director now owns 62,102 shares of the company’s stock, valued at $5,420,883.58. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.39% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This story was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://transcriptdaily.com/2019/02/12/celgene-co-celg-holdings-cut-by-arrow-financial-corp.html.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: What is a Swap?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.